Medplus Health Services Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast

CMP Rs 806.95. FY26 EPS Rs 18.3; 16% annual growth. Target 2027: Rs 835 (+3%). Target 2028: Rs 1,000. Target 2030: Rs 1,440 (+78%).

Medplus Health Services at Rs 806.95 is the second-largest pharmacy chain in India after PharmEasy and Reliance Retail Pharma, operating a hyper-clustered store footprint concentrated in Telangana, Andhra Pradesh, Tamil Nadu, and Karnataka. This geographic concentration is both Medplus’s strength (deep market penetration with competitive cluster effects) and its primary risk (limited revenue from North and West India). The Medplus Health Services share price target of Rs 835 for 2027, rising to Rs 1,440 by 2030, reflects steady South India pharmacy expansion plus a cautious view on North India replication speed.

The Medplus Health Services share price target of Rs 835 for 2027, rising to Rs 1,440 by 2030, reflects 16% annual earnings growth with a forward multiple consistent with Pharmacy Retail peers. This article covers the Medplus Health Services share price target 2027, 2028, and 2030 based on FY26 financials and analyst estimates as of August 2026.

Click Here – Get Free Investment Predictions

Medplus Health Services Company Overview

What most investors miss: MedPlus runs a hyper-clustered, largely South India store footprint. A large share of stores operate on a cluster model where proximity to each other improves last-mile fulfilment and customer stickiness. The South India pharmacy market is more organised and brand-conscious than North India, giving MedPlus a stronger competitive position in its home markets. The risk: pan-India expansion requires building similar cluster density in new markets, which is capital-intensive and time-consuming.

Assuming approximately20% annual earnings growth off a FY26 base EPS of ₹18. 3 and a fair multiple of approximately38x (moderating to approximately16% growth long-term), the stock’s valuation trend points to the figures above. The share price targets of Rs 835 for 2027, Rs 1,000 for 2028, and Rs 1,440 for 2030 are derived from this earnings trajectory and peer multiples.

Why Is the Medplus Health Services Share Price Target Set at Rs 835 for 2027

South India Cluster Model Creates Last-Mile Pharmacy Dominance

This is the foundational driver of the Medplus Health Services share price target of Rs 835 for 2027 and Rs 1,440 by 2030. Assuming approximately20% annual earnings growth off a FY26 base EPS of ₹18.3 and a fair multiple of approximately38x (moderating to approximately16% growth long-term), the stock’s valuation trend poi. The market will progressively price this as quarterly data confirms the trajectory.

Generic Drug Substitution Push by Government Benefits Pharmacy Chains

Investors analysing the Medplus Health Services share price target should track this dimension quarterly, as it provides the clearest signal of whether the compounding thesis is on track. Evidence of sustained improvement in this area is the primary re-rating catalyst for the Medplus Health Services share price target 2028 of Rs 911.

Own-Brand Generics Provide Higher Margin Revenue Versus Branded Drugs

This structural factor is often underweighted in standard Medplus Health Services share price target analyses, which focus on trailing earnings multiples rather than the competitive positioning embedded in the long-term franchise value. Its persistence through economic cycles is what differentiates the Medplus Health Services share price target 2030 case from a short-term trading call.

Health and Wellness Adjacent Products Expand Revenue Per Customer

For the Medplus Health Services share price target of Rs 1,440 to materialise by 2030, this factor needs to remain intact and compound over 4 years. Quarterly updates on this metric provide the earliest warning signal of any deviation from the Medplus Health Services share price target base case assumptions.

Digital Prescription Integration and Telehealth Partnership Potential Is Significant

As India’s economy compounds through 2027 to 2030, this factor provides an additional secular tailwind that is layered on top of the Medplus Health Services-specific earnings growth already embedded in the Rs 835 target for 2027 and the Rs 1,440 target for 2030.

Medplus Health Services Share Price Targets 2027, 2028 and 2030

Medplus Health Services Share Price Target 2027: Rs 835

The Medplus Health Services share price target 2027 is Rs 835, representing approximately 3 percent upside from CMP Rs 806.95. Assuming approximately20% annual earnings growth off a FY26 base EPS of ₹18.3 and a fair multiple of approximately38x (moderating to approximately16% growth long-term), the stock’s valuation trend points to the figures above. Street consensus (1-yr). By 2027, the key catalyst for achieving this level is validation of the earnings trajectory through 2 consecutive quarters of on-target performance.

Medplus Health Services Share Price Target 2028: Rs 1,000

The Medplus Health Services share price target 2028 is Rs 1,000, implying approximately 24 percent upside from CMP. By 2028, Medplus Health Services should have demonstrated through a full earnings cycle that the 16% growth assumption is sustainable, supporting a re-rating toward the Medplus Health Services share price target 2028 level at a forward multiple consistent with sector peers.

Medplus Health Services Share Price Target 2030: Rs 1,440

The Medplus Health Services share price target 2030 is Rs 1,440, implying approximately 78 percent upside from CMP and a 4-year CAGR of approximately 16% from current levels. By 2030, Medplus Health Services should be a mature, well-understood franchise with a track record of consistent compounding that justifies the target multiple.

Bull Case and Bear Case for the Medplus Health Services Share Price Target 2030

Bull Case: Rs 1,843

The bull case Medplus Health Services share price target of Rs 1,843 by 2030: Rs 1,800 by 2030, if Medplus successfully replicates its South India cluster model in Maharashtra and NCR, and own-brand generic penetration reaches 30 percent of revenue, significantly expanding EBITDA margins.

Bear Case: Rs 1,094

The bear case Medplus Health Services share price target of Rs 1,094 by 2030: Rs 1,050 by 2030, if North India expansion costs exceed projections, competition from Reliance Retail Pharma intensifies pricing, and own-brand generic penetration stays below 15 percent.

Key Risks to the Medplus Health Services Share Price Target

USFDA Inspection and Compliance Risk

Any USFDA warning letter or import alert on Medplus Health Services’s manufacturing facilities would delay product launches and revenue recognition, directly reducing the earnings trajectory behind the Medplus Health Services share price target. USFDA inspection history is the most important risk indicator to track.

Currency Risk on Export Revenue

Medplus Health Services’s international revenue is primarily in US dollars and euros. Any significant INR appreciation against these currencies would reduce the INR value of reported revenues and EPS, compressing the Medplus Health Services share price target earnings assumptions.

Pricing Pressure in Regulated Generic Markets

In the US and EU generic markets, pricing erosion from competition intensifies as multiple players receive approvals for the same molecule. Any acceleration in generic pricing erosion in Medplus Health Services’s key export products would compress the Medplus Health Services share price target revenue base.

Clinical Trial and Pipeline Risk

Any setback in Medplus Health Services’s clinical trial results or regulatory approvals for pipeline products would delay the revenue ramp from specialty or novel products embedded in the Medplus Health Services share price target 2028 and 2030 assumptions.

How to Invest in Medplus Health Services

Use the Univest Screener to track Medplus Health Services’s key financial metrics including EPS growth, margin trends, and analyst upgrades or downgrades in real time. To purchase shares, open a demat account with any SEBI-registered broker and search for NSE ticker MEDPLUS. Review the quarterly earnings data, the sector-specific risk indicators outlined in this article, and build a position size proportionate to your risk tolerance and investment horizon. Monitor each quarter for the key variables most likely to move the Medplus Health Services share price target. Consult a SEBI-registered financial advisor before making any investment decision.

Use the Univest Screener to Track This Stock Live

Conclusion

The Medplus Health Services share price target of Rs 835 for 2027, Rs 1,000 for 2028, and Rs 1,440 for 2030 reflects 16% annual earnings compounding and a forward multiple consistent with Pharmacy Retail peers. The key drivers and risks are outlined above. MedPlus runs a hyper-clustered, largely South India store footprint. A large share of stores operate on a cluster model where proximity to each other. For investors with a 3 to 4 year horizon and a tolerance for Pharmacy Retail-specific risk, the current CMP of Rs 806.95 offers a starting point for building a position aligned to the Medplus Health Services share price target 2030 thesis. Always verify data at NSE and BSE before investing.

Download the Univest iOS App or Univest Android App to track Medplus Health Services share price live and get daily stock recommendations.

Frequently Asked Questions on Medplus Health Services Share Price Target 2027 2028 and 2030

What is the Medplus Health Services share price target for 2027?

Ans. The Medplus Health Services share price target for 2027 is Rs 835, representing approximately 3 percent upside from CMP Rs 806.95 as of August 2026. Please verify all data with the official NSE website before making any investment decision.

What is the Medplus Health Services share price target for 2030?

Ans. The Medplus Health Services share price target for 2030 is Rs 1,440, implying approximately 78 percent upside from CMP Rs 806.95. This is based on analyst estimates and is not a guaranteed return. Always verify current data at NSE India before investing.

Is Medplus Health Services a good long-term investment?

Ans. Medplus Health Services has a defined analyst consensus that projects earnings compounding through FY31 based on sector-specific growth drivers outlined in this article. Whether it suits your portfolio depends on your risk appetite, investment horizon, and existing allocation. Consult a SEBI-registered financial advisor for personalised guidance.

What do most investors miss about Medplus Health Services?

Ans. MedPlus runs a hyper-clustered, largely South-India store footprint (bulk of stores in Telangana/AP/Tamil Nadu/Karnataka), so it carries real geographic concentration risk; a large share of stores are still in their loss-making maturation window, which suppresses blended margins – steady-state econo

What is the bull case for the Medplus Health Services share price target 2030?

Ans. The bull case Medplus Health Services share price target for 2030 is Rs 1,843. This requires better-than-base-case execution on the key growth drivers specific to Medplus Health Services’s sector, as described in this article. These are analyst projections, not guaranteed returns.

What are the main risks to the Medplus Health Services share price target?

Ans. The key risks to the Medplus Health Services share price target include sector-specific headwinds such as credit cycles (for financial companies), regulatory changes, competitive pressure, and macroeconomic slowdown. Please review the risks section of this article for a full breakdown of the four most material risks.

What is Medplus Health Services’s 52-week high and low share price?

Ans. As of August 2026, Medplus Health Services’s 52-week high is approximately Rs 1,200 and the 52-week low is approximately Rs 680. The CMP of Rs 806.95 sits between these levels. Always verify the latest 52-week data at NSE India or BSE before making any investment decision.

How can I buy Medplus Health Services shares?

Ans. You can buy Medplus Health Services shares through any SEBI-registered broker by searching for the NSE ticker MEDPLUS. Before investing, review the fundamentals outlined in this article and consult a SEBI-registered financial advisor for guidance aligned to your specific financial goals.